Clinical Edge Journal Scan

Key clinical point: Compared with control individuals without psoriatic arthritis (PsA), the burden of headache and migraine without aura was significantly higher in patients with PsA.

Major finding: The prevalence of headache (39.81% vs 26.44%; P = .028) and migraine without aura (18.52% vs 9.2%; P = .044) was significantly higher in patients with PsA vs control individuals without PsA. Patients with PsA who did vs did not have headaches also presented with a higher burden of comorbidities and prevalence of enthesitis (P = .02 for both).

Study details: This cross-sectional, observational cohort study included 216 patients with PsA, 70 patients with axial spondyloarthritis, and 87 gender-matched control individuals.

Disclosures: This study did not receive any external funding. The authors declared no conflicts of interest.

Source: Marino A, Currado D, Altamura C, et al. Increased prevalence of headaches and migraine in patients with psoriatic arthritis and axial spondyloarthritis: Insights from an Italian cohort study. Biomedicines. 2024;12(2):371. doi: 10.3390/biomedicines12020371 Source

Key clinical point: Compared with control individuals without psoriatic arthritis (PsA), the burden of headache and migraine without aura was significantly higher in patients with PsA.

Major finding: The prevalence of headache (39.81% vs 26.44%; P = .028) and migraine without aura (18.52% vs 9.2%; P = .044) was significantly higher in patients with PsA vs control individuals without PsA. Patients with PsA who did vs did not have headaches also presented with a higher burden of comorbidities and prevalence of enthesitis (P = .02 for both).

Study details: This cross-sectional, observational cohort study included 216 patients with PsA, 70 patients with axial spondyloarthritis, and 87 gender-matched control individuals.

Disclosures: This study did not receive any external funding. The authors declared no conflicts of interest.

Source: Marino A, Currado D, Altamura C, et al. Increased prevalence of headaches and migraine in patients with psoriatic arthritis and axial spondyloarthritis: Insights from an Italian cohort study. Biomedicines. 2024;12(2):371. doi: 10.3390/biomedicines12020371 Source

Key clinical point: Compared with control individuals without psoriatic arthritis (PsA), the burden of headache and migraine without aura was significantly higher in patients with PsA.

Major finding: The prevalence of headache (39.81% vs 26.44%; P = .028) and migraine without aura (18.52% vs 9.2%; P = .044) was significantly higher in patients with PsA vs control individuals without PsA. Patients with PsA who did vs did not have headaches also presented with a higher burden of comorbidities and prevalence of enthesitis (P = .02 for both).

Study details: This cross-sectional, observational cohort study included 216 patients with PsA, 70 patients with axial spondyloarthritis, and 87 gender-matched control individuals.

Disclosures: This study did not receive any external funding. The authors declared no conflicts of interest.

Source: Marino A, Currado D, Altamura C, et al. Increased prevalence of headaches and migraine in patients with psoriatic arthritis and axial spondyloarthritis: Insights from an Italian cohort study. Biomedicines. 2024;12(2):371. doi: 10.3390/biomedicines12020371 Source

Key clinical point: In patients with psoriatic arthritis (PsA), etanercept improved disease remission in routine clinical practice without showing any new safety signals.

Major finding: At week 12, 38.3% of patients with PsA achieved disease remission, with the proportion of patients achieving remission increasing to 51% and 54% at weeks 24 and 52, respectively. Among patients who achieved remission at week 12, 52.2% maintained it up to week 52. The most common treatment-emergent serious adverse events were aggravated condition, injury, poisoning, procedural complications, cardiac disorders, gastrointestinal disorders, and neoplasms.

Study details: Findings are from the prospective, non-interventional ADEQUATE study including patients with PsA (n = 254), axial spondyloarthritis (n = 305), or psoriasis (n = 70) who received etanercept for up to 52 weeks.

Disclosures: This study was funded by Pfizer Pharma GmbH. Three authors declared being employees and shareholders of Pfizer. Other authors declared receiving consulting fees, speaker fees, honoraria, or grants from or having other ties with various sources, including Pfizer.

Source: Feist E, Baraliakos X, Behrens F, et al. Etanercept in axial spondyloarthritis, psoriatic arthritis, and plaque psoriasis: Real-world outcome data from German non-interventional study ADEQUATE. Rheumatol Ther. 2024 (Feb 3). doi: 10.1007/s40744-023-00633-2  Source

Key clinical point: In patients with psoriatic arthritis (PsA), etanercept improved disease remission in routine clinical practice without showing any new safety signals.

Major finding: At week 12, 38.3% of patients with PsA achieved disease remission, with the proportion of patients achieving remission increasing to 51% and 54% at weeks 24 and 52, respectively. Among patients who achieved remission at week 12, 52.2% maintained it up to week 52. The most common treatment-emergent serious adverse events were aggravated condition, injury, poisoning, procedural complications, cardiac disorders, gastrointestinal disorders, and neoplasms.

Study details: Findings are from the prospective, non-interventional ADEQUATE study including patients with PsA (n = 254), axial spondyloarthritis (n = 305), or psoriasis (n = 70) who received etanercept for up to 52 weeks.

Disclosures: This study was funded by Pfizer Pharma GmbH. Three authors declared being employees and shareholders of Pfizer. Other authors declared receiving consulting fees, speaker fees, honoraria, or grants from or having other ties with various sources, including Pfizer.

Source: Feist E, Baraliakos X, Behrens F, et al. Etanercept in axial spondyloarthritis, psoriatic arthritis, and plaque psoriasis: Real-world outcome data from German non-interventional study ADEQUATE. Rheumatol Ther. 2024 (Feb 3). doi: 10.1007/s40744-023-00633-2  Source

Key clinical point: In patients with psoriatic arthritis (PsA), etanercept improved disease remission in routine clinical practice without showing any new safety signals.

Major finding: At week 12, 38.3% of patients with PsA achieved disease remission, with the proportion of patients achieving remission increasing to 51% and 54% at weeks 24 and 52, respectively. Among patients who achieved remission at week 12, 52.2% maintained it up to week 52. The most common treatment-emergent serious adverse events were aggravated condition, injury, poisoning, procedural complications, cardiac disorders, gastrointestinal disorders, and neoplasms.

Study details: Findings are from the prospective, non-interventional ADEQUATE study including patients with PsA (n = 254), axial spondyloarthritis (n = 305), or psoriasis (n = 70) who received etanercept for up to 52 weeks.

Disclosures: This study was funded by Pfizer Pharma GmbH. Three authors declared being employees and shareholders of Pfizer. Other authors declared receiving consulting fees, speaker fees, honoraria, or grants from or having other ties with various sources, including Pfizer.

Source: Feist E, Baraliakos X, Behrens F, et al. Etanercept in axial spondyloarthritis, psoriatic arthritis, and plaque psoriasis: Real-world outcome data from German non-interventional study ADEQUATE. Rheumatol Ther. 2024 (Feb 3). doi: 10.1007/s40744-023-00633-2  Source

Key clinical point: Patients with multimorbid psoriasis should be monitored for the potential development of psoriatic arthritis (PsA) as the presence of ≥2 morbidities at psoriasis incidence has been associated with an increased risk for PsA.

Major finding: The cumulative incidence of PsA in patients with psoriasis was 1.7%, 2.5%, and 2.9% at 5, 10, and 15 years after psoriasis incidence, respectively, with the risk for PsA being higher in those with ≥2 morbidities (hazard ratio 2.46; 95% CI 1.01-6.01).

Study details: Findings are from a retrospective cohort study including 817 patients with incident psoriasis and 849 age- and sex-matched comparator individuals without psoriasis; of these, 23 patients with psoriasis developed PsA during a median follow-up of 13.3 years.

Disclosures: This study was sponsored by the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) and other sources. Two authors declared serving as consultants for or receiving research support and grants from various sources.

Source: Karmacharya P, Chakradhar R, Hulshizer CA, et al. Multimorbidity in psoriasis as a risk factor for psoriatic arthritis: A population-based study. Rheumatology (Oxford). 2024 (Jan 30). doi: 10.1093/rheumatology/keae040 Source

Key clinical point: Patients with multimorbid psoriasis should be monitored for the potential development of psoriatic arthritis (PsA) as the presence of ≥2 morbidities at psoriasis incidence has been associated with an increased risk for PsA.

Major finding: The cumulative incidence of PsA in patients with psoriasis was 1.7%, 2.5%, and 2.9% at 5, 10, and 15 years after psoriasis incidence, respectively, with the risk for PsA being higher in those with ≥2 morbidities (hazard ratio 2.46; 95% CI 1.01-6.01).

Study details: Findings are from a retrospective cohort study including 817 patients with incident psoriasis and 849 age- and sex-matched comparator individuals without psoriasis; of these, 23 patients with psoriasis developed PsA during a median follow-up of 13.3 years.

Disclosures: This study was sponsored by the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) and other sources. Two authors declared serving as consultants for or receiving research support and grants from various sources.

Source: Karmacharya P, Chakradhar R, Hulshizer CA, et al. Multimorbidity in psoriasis as a risk factor for psoriatic arthritis: A population-based study. Rheumatology (Oxford). 2024 (Jan 30). doi: 10.1093/rheumatology/keae040 Source

Key clinical point: Patients with multimorbid psoriasis should be monitored for the potential development of psoriatic arthritis (PsA) as the presence of ≥2 morbidities at psoriasis incidence has been associated with an increased risk for PsA.

Major finding: The cumulative incidence of PsA in patients with psoriasis was 1.7%, 2.5%, and 2.9% at 5, 10, and 15 years after psoriasis incidence, respectively, with the risk for PsA being higher in those with ≥2 morbidities (hazard ratio 2.46; 95% CI 1.01-6.01).

Study details: Findings are from a retrospective cohort study including 817 patients with incident psoriasis and 849 age- and sex-matched comparator individuals without psoriasis; of these, 23 patients with psoriasis developed PsA during a median follow-up of 13.3 years.

Disclosures: This study was sponsored by the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) and other sources. Two authors declared serving as consultants for or receiving research support and grants from various sources.

Source: Karmacharya P, Chakradhar R, Hulshizer CA, et al. Multimorbidity in psoriasis as a risk factor for psoriatic arthritis: A population-based study. Rheumatology (Oxford). 2024 (Jan 30). doi: 10.1093/rheumatology/keae040 Source

Key clinical point: Elevated baseline levels of interleukin (IL)-22, IL-17A, and β-defensin (BD)-2 were linked to the achievement of robust skin response with guselkumab in difficult to treat patients with psoriatic arthritis (PsA) who showed inadequate response to tumor necrosis factor inhibitors (TNFi-IR).

Major finding: Levels of IL-22 and BD-2 were elevated in TNFi-IR patients with PsA who did vs did not achieve a ≥90% improvement in Psoriasis Area and Severity Index with guselkumab (P < .05). Levels of IL-17A and BD-2 were similarly elevated in patients who did vs did not respond to Investigator’s Global Assessment 0/1 criteria with guselkumab (all P < .05).

Study details: This post hoc analysis of pooled data from DISCOVER-1, DISCOVER-2, and COSMOS studies included patients with active PsA who were biologic-naive (n = 251) or had TNFi-IR (n = 93) and who received 100 mg guselkumab every 8 weeks.

Disclosures: This study was sponsored by Janssen Research & Development. Ten authors declared being employees of Janssen or subsidiaries or owning stocks or stock options in Johnson & Johnson. Several authors declared other ties with various sources, including Janssen. Other authors had no conflicts of interest.

Source: Siebert S, Coates LC, Schett G, et al. Modulation of IL-23 signaling with guselkumab in biologic-naïve patients versus TNF inhibitor-inadequate responders with active psoriatic arthritis. Arthritis Rheumatol. 2024 (Jan 22). doi: 10.1002/art.42803 Source

Key clinical point: Elevated baseline levels of interleukin (IL)-22, IL-17A, and β-defensin (BD)-2 were linked to the achievement of robust skin response with guselkumab in difficult to treat patients with psoriatic arthritis (PsA) who showed inadequate response to tumor necrosis factor inhibitors (TNFi-IR).

Major finding: Levels of IL-22 and BD-2 were elevated in TNFi-IR patients with PsA who did vs did not achieve a ≥90% improvement in Psoriasis Area and Severity Index with guselkumab (P < .05). Levels of IL-17A and BD-2 were similarly elevated in patients who did vs did not respond to Investigator’s Global Assessment 0/1 criteria with guselkumab (all P < .05).

Study details: This post hoc analysis of pooled data from DISCOVER-1, DISCOVER-2, and COSMOS studies included patients with active PsA who were biologic-naive (n = 251) or had TNFi-IR (n = 93) and who received 100 mg guselkumab every 8 weeks.

Disclosures: This study was sponsored by Janssen Research & Development. Ten authors declared being employees of Janssen or subsidiaries or owning stocks or stock options in Johnson & Johnson. Several authors declared other ties with various sources, including Janssen. Other authors had no conflicts of interest.

Source: Siebert S, Coates LC, Schett G, et al. Modulation of IL-23 signaling with guselkumab in biologic-naïve patients versus TNF inhibitor-inadequate responders with active psoriatic arthritis. Arthritis Rheumatol. 2024 (Jan 22). doi: 10.1002/art.42803 Source

Key clinical point: Elevated baseline levels of interleukin (IL)-22, IL-17A, and β-defensin (BD)-2 were linked to the achievement of robust skin response with guselkumab in difficult to treat patients with psoriatic arthritis (PsA) who showed inadequate response to tumor necrosis factor inhibitors (TNFi-IR).

Major finding: Levels of IL-22 and BD-2 were elevated in TNFi-IR patients with PsA who did vs did not achieve a ≥90% improvement in Psoriasis Area and Severity Index with guselkumab (P < .05). Levels of IL-17A and BD-2 were similarly elevated in patients who did vs did not respond to Investigator’s Global Assessment 0/1 criteria with guselkumab (all P < .05).

Study details: This post hoc analysis of pooled data from DISCOVER-1, DISCOVER-2, and COSMOS studies included patients with active PsA who were biologic-naive (n = 251) or had TNFi-IR (n = 93) and who received 100 mg guselkumab every 8 weeks.

Disclosures: This study was sponsored by Janssen Research & Development. Ten authors declared being employees of Janssen or subsidiaries or owning stocks or stock options in Johnson & Johnson. Several authors declared other ties with various sources, including Janssen. Other authors had no conflicts of interest.

Source: Siebert S, Coates LC, Schett G, et al. Modulation of IL-23 signaling with guselkumab in biologic-naïve patients versus TNF inhibitor-inadequate responders with active psoriatic arthritis. Arthritis Rheumatol. 2024 (Jan 22). doi: 10.1002/art.42803 Source

Key clinical point: Compared with the general population, the prevalence of psychotic disorders was significantly lower in patients with psoriatic arthritis (PsA), but a co-diagnosis of PsA and psychotic disorders was associated with an increased mortality rate, that too at a lower age.

Major finding: The prevalence of psychotic disorders was significantly lower in patients with PsA vs the general population (0.61% vs 0.72%; P = .006). Patients with PsA who did vs did not have psychotic disorders had an increased likelihood of death (9.3% vs 4.9%; P = .005) and significantly lower age at death (64.7 years vs 74.5 years; P < .001).

Study details: This cohort study included 449,392 patients with psoriasis and 47,825 patients with PsA.

Disclosures: The lead author Emilie Brenaut declared receiving a postdoctoral fellowship from the French Society of Dermatology and the Collège des Enseignants en Dermatologie de France as well as personal fees and nonfinancial support from various sources. The other authors reported no conflicts of interest.

Source: Brenaut E, Godin O, Leboyer M, et al. Association between psychotic disorders and psoriasis or psoriatic arthritis: Cohort study of French health insurance database. J Invest Dermatol. 2024 (Jan 19). doi: 10.1016/j.jid.2024.01.005  Source

Key clinical point: Compared with the general population, the prevalence of psychotic disorders was significantly lower in patients with psoriatic arthritis (PsA), but a co-diagnosis of PsA and psychotic disorders was associated with an increased mortality rate, that too at a lower age.

Major finding: The prevalence of psychotic disorders was significantly lower in patients with PsA vs the general population (0.61% vs 0.72%; P = .006). Patients with PsA who did vs did not have psychotic disorders had an increased likelihood of death (9.3% vs 4.9%; P = .005) and significantly lower age at death (64.7 years vs 74.5 years; P < .001).

Study details: This cohort study included 449,392 patients with psoriasis and 47,825 patients with PsA.

Disclosures: The lead author Emilie Brenaut declared receiving a postdoctoral fellowship from the French Society of Dermatology and the Collège des Enseignants en Dermatologie de France as well as personal fees and nonfinancial support from various sources. The other authors reported no conflicts of interest.

Source: Brenaut E, Godin O, Leboyer M, et al. Association between psychotic disorders and psoriasis or psoriatic arthritis: Cohort study of French health insurance database. J Invest Dermatol. 2024 (Jan 19). doi: 10.1016/j.jid.2024.01.005  Source

Key clinical point: Compared with the general population, the prevalence of psychotic disorders was significantly lower in patients with psoriatic arthritis (PsA), but a co-diagnosis of PsA and psychotic disorders was associated with an increased mortality rate, that too at a lower age.

Major finding: The prevalence of psychotic disorders was significantly lower in patients with PsA vs the general population (0.61% vs 0.72%; P = .006). Patients with PsA who did vs did not have psychotic disorders had an increased likelihood of death (9.3% vs 4.9%; P = .005) and significantly lower age at death (64.7 years vs 74.5 years; P < .001).

Study details: This cohort study included 449,392 patients with psoriasis and 47,825 patients with PsA.

Disclosures: The lead author Emilie Brenaut declared receiving a postdoctoral fellowship from the French Society of Dermatology and the Collège des Enseignants en Dermatologie de France as well as personal fees and nonfinancial support from various sources. The other authors reported no conflicts of interest.

Source: Brenaut E, Godin O, Leboyer M, et al. Association between psychotic disorders and psoriasis or psoriatic arthritis: Cohort study of French health insurance database. J Invest Dermatol. 2024 (Jan 19). doi: 10.1016/j.jid.2024.01.005  Source

Key clinical point: Tofacitinib improved disease activity outcomes and clinical manifestations in patients with psoriatic arthritis (PsA) who initiated and continued treatment with tofacitinib.

Major finding: At 6 ± 3 months of follow-up, 25.0% and 7.8% of patients achieved Clinical Disease Activity Index for PsA-defined low disease activity and remission, respectively, and 18.2% of patients achieved minimal disease activity. A substantial proportion of patients also reported the resolution of dactylitis (29.4%) and enthesitis (42.9%).

Study details: Findings are from an observational study including 222 patients with PsA from the CorEvitas PsA/Spondyloarthritis Registry who initiated treatment with tofacitinib, of whom 123 patients had 6 ± 3 months of follow-up.

Disclosures: This study was funded by Pfizer. Four authors declared being employees and stockholders of Pfizer Inc. The other authors declared having ties with various sources, including Pfizer.

Source: Mease PJ, Young P, Fallon L, et al. Effectiveness of tofacitinib in patients initiating therapy for psoriatic arthritis: Results from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry. Rheumatol Ther. 2024 (Jan 22). doi: 10.1007/s40744-023-00631-4 Source

Key clinical point: Tofacitinib improved disease activity outcomes and clinical manifestations in patients with psoriatic arthritis (PsA) who initiated and continued treatment with tofacitinib.

Major finding: At 6 ± 3 months of follow-up, 25.0% and 7.8% of patients achieved Clinical Disease Activity Index for PsA-defined low disease activity and remission, respectively, and 18.2% of patients achieved minimal disease activity. A substantial proportion of patients also reported the resolution of dactylitis (29.4%) and enthesitis (42.9%).

Study details: Findings are from an observational study including 222 patients with PsA from the CorEvitas PsA/Spondyloarthritis Registry who initiated treatment with tofacitinib, of whom 123 patients had 6 ± 3 months of follow-up.

Disclosures: This study was funded by Pfizer. Four authors declared being employees and stockholders of Pfizer Inc. The other authors declared having ties with various sources, including Pfizer.

Source: Mease PJ, Young P, Fallon L, et al. Effectiveness of tofacitinib in patients initiating therapy for psoriatic arthritis: Results from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry. Rheumatol Ther. 2024 (Jan 22). doi: 10.1007/s40744-023-00631-4 Source

Key clinical point: Tofacitinib improved disease activity outcomes and clinical manifestations in patients with psoriatic arthritis (PsA) who initiated and continued treatment with tofacitinib.

Major finding: At 6 ± 3 months of follow-up, 25.0% and 7.8% of patients achieved Clinical Disease Activity Index for PsA-defined low disease activity and remission, respectively, and 18.2% of patients achieved minimal disease activity. A substantial proportion of patients also reported the resolution of dactylitis (29.4%) and enthesitis (42.9%).

Study details: Findings are from an observational study including 222 patients with PsA from the CorEvitas PsA/Spondyloarthritis Registry who initiated treatment with tofacitinib, of whom 123 patients had 6 ± 3 months of follow-up.

Disclosures: This study was funded by Pfizer. Four authors declared being employees and stockholders of Pfizer Inc. The other authors declared having ties with various sources, including Pfizer.

Source: Mease PJ, Young P, Fallon L, et al. Effectiveness of tofacitinib in patients initiating therapy for psoriatic arthritis: Results from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry. Rheumatol Ther. 2024 (Jan 22). doi: 10.1007/s40744-023-00631-4 Source

Key clinical point: In patients with moderate to severe psoriatic arthritis (PsA), risankizumab demonstrated superior efficacy vs placebo in improving disease activity outcomes with a favorable safety profile.

Major finding: A significantly higher number of patients receiving risankizumab vs placebo achieved more than 20% improvement in American College of Rheumatology score at week 24 (risk ratio [RR] 1.760; P < .001) and higher minimal disease activity response (RR 1.827; P < .05). The incidences of serious adverse events and serious treatment-emergent adverse events were similar between the risankizumab and placebo groups (P = .31 and P = .97, respectively).

Study details: This meta-analysis of six randomized controlled trials included 5038 patients with PsA who received either risankizumab or placebo.

Disclosures: This study was supported by grants from the National Natural Science Foundation of China and the Natural Science Foundation of Shanxi Province. The authors declared no conflicts of interest.

Source: Su QY, Zhou HN, Xia GM, et al. Efficacy and safety of risankizumab in patients with psoriatic arthritis: A systematic review and meta-analysis of randomized controlled trials. Rheumatol Ther. 2024 (Feb 1). doi: 10.1007/s40744-024-00638-5 Source

Key clinical point: In patients with moderate to severe psoriatic arthritis (PsA), risankizumab demonstrated superior efficacy vs placebo in improving disease activity outcomes with a favorable safety profile.

Major finding: A significantly higher number of patients receiving risankizumab vs placebo achieved more than 20% improvement in American College of Rheumatology score at week 24 (risk ratio [RR] 1.760; P < .001) and higher minimal disease activity response (RR 1.827; P < .05). The incidences of serious adverse events and serious treatment-emergent adverse events were similar between the risankizumab and placebo groups (P = .31 and P = .97, respectively).

Study details: This meta-analysis of six randomized controlled trials included 5038 patients with PsA who received either risankizumab or placebo.

Disclosures: This study was supported by grants from the National Natural Science Foundation of China and the Natural Science Foundation of Shanxi Province. The authors declared no conflicts of interest.

Source: Su QY, Zhou HN, Xia GM, et al. Efficacy and safety of risankizumab in patients with psoriatic arthritis: A systematic review and meta-analysis of randomized controlled trials. Rheumatol Ther. 2024 (Feb 1). doi: 10.1007/s40744-024-00638-5 Source

Key clinical point: In patients with moderate to severe psoriatic arthritis (PsA), risankizumab demonstrated superior efficacy vs placebo in improving disease activity outcomes with a favorable safety profile.

Major finding: A significantly higher number of patients receiving risankizumab vs placebo achieved more than 20% improvement in American College of Rheumatology score at week 24 (risk ratio [RR] 1.760; P < .001) and higher minimal disease activity response (RR 1.827; P < .05). The incidences of serious adverse events and serious treatment-emergent adverse events were similar between the risankizumab and placebo groups (P = .31 and P = .97, respectively).

Study details: This meta-analysis of six randomized controlled trials included 5038 patients with PsA who received either risankizumab or placebo.

Disclosures: This study was supported by grants from the National Natural Science Foundation of China and the Natural Science Foundation of Shanxi Province. The authors declared no conflicts of interest.

Source: Su QY, Zhou HN, Xia GM, et al. Efficacy and safety of risankizumab in patients with psoriatic arthritis: A systematic review and meta-analysis of randomized controlled trials. Rheumatol Ther. 2024 (Feb 1). doi: 10.1007/s40744-024-00638-5 Source

Key clinical point: Patients with psoriatic arthritis (PsA) showed improvements in enthesitis scores on receiving 15 mg upadacitinib for 24 weeks, with the improvements being maintained for ≤56 weeks.

Major finding: At week 24, a significantly higher proportion of patients achieved a greater improvement in the Leeds Enthesitis Index (LEI) score with 15 mg upadacitinib vs placebo (59.8% vs 38.0%; P < .001), with the improvements being maintained by >65% of patients receiving upadacitinib at week 56. Among patients who achieved resolution (LEI = 0) at week 24, >80% did not have recurrent enthesitis with upadacitinib at week 56.

Study details: This post hoc analysis of the SELECT-PsA 1 and SELECT-PsA 2 trials analyzed the data of patients with PsA who received 15 mg upadacitinib (n = 639) or placebo (n = 635).

Disclosures: This study was funded by AbbVie. Five authors declared being employees of or holding stocks or stock options with AbbVie. Two authors declared receiving consulting fees from or having other ties with various sources, including AbbVie. Fabrizio Cantini declared no conflicts of interest.

Source: Cantini F, Marchesoni A, Novelli L, et al. Effects of upadacitinib on enthesitis in patients with psoriatic arthritis: A post hoc analysis of SELECT-PsA 1 and 2. Rheumatology (Oxford). 2024 (Feb 8). doi: 10.1093/rheumatology/keae057 Source

Key clinical point: Patients with psoriatic arthritis (PsA) showed improvements in enthesitis scores on receiving 15 mg upadacitinib for 24 weeks, with the improvements being maintained for ≤56 weeks.

Major finding: At week 24, a significantly higher proportion of patients achieved a greater improvement in the Leeds Enthesitis Index (LEI) score with 15 mg upadacitinib vs placebo (59.8% vs 38.0%; P < .001), with the improvements being maintained by >65% of patients receiving upadacitinib at week 56. Among patients who achieved resolution (LEI = 0) at week 24, >80% did not have recurrent enthesitis with upadacitinib at week 56.

Study details: This post hoc analysis of the SELECT-PsA 1 and SELECT-PsA 2 trials analyzed the data of patients with PsA who received 15 mg upadacitinib (n = 639) or placebo (n = 635).

Disclosures: This study was funded by AbbVie. Five authors declared being employees of or holding stocks or stock options with AbbVie. Two authors declared receiving consulting fees from or having other ties with various sources, including AbbVie. Fabrizio Cantini declared no conflicts of interest.

Source: Cantini F, Marchesoni A, Novelli L, et al. Effects of upadacitinib on enthesitis in patients with psoriatic arthritis: A post hoc analysis of SELECT-PsA 1 and 2. Rheumatology (Oxford). 2024 (Feb 8). doi: 10.1093/rheumatology/keae057 Source

Key clinical point: Patients with psoriatic arthritis (PsA) showed improvements in enthesitis scores on receiving 15 mg upadacitinib for 24 weeks, with the improvements being maintained for ≤56 weeks.

Major finding: At week 24, a significantly higher proportion of patients achieved a greater improvement in the Leeds Enthesitis Index (LEI) score with 15 mg upadacitinib vs placebo (59.8% vs 38.0%; P < .001), with the improvements being maintained by >65% of patients receiving upadacitinib at week 56. Among patients who achieved resolution (LEI = 0) at week 24, >80% did not have recurrent enthesitis with upadacitinib at week 56.

Study details: This post hoc analysis of the SELECT-PsA 1 and SELECT-PsA 2 trials analyzed the data of patients with PsA who received 15 mg upadacitinib (n = 639) or placebo (n = 635).

Disclosures: This study was funded by AbbVie. Five authors declared being employees of or holding stocks or stock options with AbbVie. Two authors declared receiving consulting fees from or having other ties with various sources, including AbbVie. Fabrizio Cantini declared no conflicts of interest.

Source: Cantini F, Marchesoni A, Novelli L, et al. Effects of upadacitinib on enthesitis in patients with psoriatic arthritis: A post hoc analysis of SELECT-PsA 1 and 2. Rheumatology (Oxford). 2024 (Feb 8). doi: 10.1093/rheumatology/keae057 Source

Key clinical point: Neuropathic pain (NP) led to an increase in obesity-associated factors, such as high serum leptin levels and worsened sleep quality, disease activity outcomes, and fatigue levels in patients with psoriatic arthritis (PsA) who did not have fibromyalgia.

Major finding: Patients with PsA who reported NP vs nociceptive pain had higher serum leptin levels (odds ratio [OR] 1.03; 95% CI 1.007-1.056) and poor sleep quality as assessed by the Insomnia Severity Index score (OR 1.19; 95% CI 1.090-1.297), along with greater fatigue, increased PsA disease activity, poor functioning, and higher disease impact (all P < .001).

Study details: Findings are from a cross-sectional study that included 246 patients with PsA who were not diagnosed with fibromyalgia, depression, anxiety, diabetes, or dyslipidemia.

Disclosures: The study authors declared receiving financial support for the research, authorship, and publication of this study. The authors declared no conflicts of interest.

Source: Toledano E, Queiro R, Gomez-Lechon L, et al. Influence of comorbidities not associated with fibromyalgia on neuropathic pain in patients with psoriatic arthritis: Relationship with clinical parameters. Front Med (Lausanne). 2024;11:1331761 (Jan 24). doi: 10.3389/fmed.2024.1331761 Source

Key clinical point: Neuropathic pain (NP) led to an increase in obesity-associated factors, such as high serum leptin levels and worsened sleep quality, disease activity outcomes, and fatigue levels in patients with psoriatic arthritis (PsA) who did not have fibromyalgia.

Major finding: Patients with PsA who reported NP vs nociceptive pain had higher serum leptin levels (odds ratio [OR] 1.03; 95% CI 1.007-1.056) and poor sleep quality as assessed by the Insomnia Severity Index score (OR 1.19; 95% CI 1.090-1.297), along with greater fatigue, increased PsA disease activity, poor functioning, and higher disease impact (all P < .001).

Study details: Findings are from a cross-sectional study that included 246 patients with PsA who were not diagnosed with fibromyalgia, depression, anxiety, diabetes, or dyslipidemia.

Disclosures: The study authors declared receiving financial support for the research, authorship, and publication of this study. The authors declared no conflicts of interest.

Source: Toledano E, Queiro R, Gomez-Lechon L, et al. Influence of comorbidities not associated with fibromyalgia on neuropathic pain in patients with psoriatic arthritis: Relationship with clinical parameters. Front Med (Lausanne). 2024;11:1331761 (Jan 24). doi: 10.3389/fmed.2024.1331761 Source

Key clinical point: Neuropathic pain (NP) led to an increase in obesity-associated factors, such as high serum leptin levels and worsened sleep quality, disease activity outcomes, and fatigue levels in patients with psoriatic arthritis (PsA) who did not have fibromyalgia.

Major finding: Patients with PsA who reported NP vs nociceptive pain had higher serum leptin levels (odds ratio [OR] 1.03; 95% CI 1.007-1.056) and poor sleep quality as assessed by the Insomnia Severity Index score (OR 1.19; 95% CI 1.090-1.297), along with greater fatigue, increased PsA disease activity, poor functioning, and higher disease impact (all P < .001).

Study details: Findings are from a cross-sectional study that included 246 patients with PsA who were not diagnosed with fibromyalgia, depression, anxiety, diabetes, or dyslipidemia.

Disclosures: The study authors declared receiving financial support for the research, authorship, and publication of this study. The authors declared no conflicts of interest.

Source: Toledano E, Queiro R, Gomez-Lechon L, et al. Influence of comorbidities not associated with fibromyalgia on neuropathic pain in patients with psoriatic arthritis: Relationship with clinical parameters. Front Med (Lausanne). 2024;11:1331761 (Jan 24). doi: 10.3389/fmed.2024.1331761 Source

Key clinical point: Patients with psoriatic arthritis (PsA) had significantly higher levels of aortic vascular inflammation as measured by 18-fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) scanning than control individuals without PsA who had melanoma.

Major finding: Vascular inflammation of the whole aorta was significantly increased in patients with PsA vs control individuals (mean target-to-background ratio 1.63 vs 1.49; P < .001), with the association remaining significant even after adjusting for gender, age, body mass index, mean arterial pressure, and aortic calcification (P = .002). Patients with PsA vs control individuals also had a higher extent of inflammation in other aortic segments.

Study details: Findings are from cross-sectional study that included 75 patients with active PsA and 40 control individuals without PsA who were diagnosed with melanoma without distant metastases, all of whom underwent FDG PET/CT scans.

Disclosures: This study was funded by Health Holland and Pfizer. Four authors declared serving as consultants or advisors for, receiving research grants from, or having other ties with various sources, including Pfizer.

Source: Kleinrensink NJ, Spierings J, Vonkeman HE, et al. Increased vascular inflammation on PET/CT in psoriatic arthritis patients in comparison with controls. RMD open. 2024;10:e003547 (Jan 30). doi: 10.1136/rmdopen-2023-003547 Source

Key clinical point: Patients with psoriatic arthritis (PsA) had significantly higher levels of aortic vascular inflammation as measured by 18-fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) scanning than control individuals without PsA who had melanoma.

Major finding: Vascular inflammation of the whole aorta was significantly increased in patients with PsA vs control individuals (mean target-to-background ratio 1.63 vs 1.49; P < .001), with the association remaining significant even after adjusting for gender, age, body mass index, mean arterial pressure, and aortic calcification (P = .002). Patients with PsA vs control individuals also had a higher extent of inflammation in other aortic segments.

Study details: Findings are from cross-sectional study that included 75 patients with active PsA and 40 control individuals without PsA who were diagnosed with melanoma without distant metastases, all of whom underwent FDG PET/CT scans.

Disclosures: This study was funded by Health Holland and Pfizer. Four authors declared serving as consultants or advisors for, receiving research grants from, or having other ties with various sources, including Pfizer.

Source: Kleinrensink NJ, Spierings J, Vonkeman HE, et al. Increased vascular inflammation on PET/CT in psoriatic arthritis patients in comparison with controls. RMD open. 2024;10:e003547 (Jan 30). doi: 10.1136/rmdopen-2023-003547 Source

Key clinical point: Patients with psoriatic arthritis (PsA) had significantly higher levels of aortic vascular inflammation as measured by 18-fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) scanning than control individuals without PsA who had melanoma.

Major finding: Vascular inflammation of the whole aorta was significantly increased in patients with PsA vs control individuals (mean target-to-background ratio 1.63 vs 1.49; P < .001), with the association remaining significant even after adjusting for gender, age, body mass index, mean arterial pressure, and aortic calcification (P = .002). Patients with PsA vs control individuals also had a higher extent of inflammation in other aortic segments.

Study details: Findings are from cross-sectional study that included 75 patients with active PsA and 40 control individuals without PsA who were diagnosed with melanoma without distant metastases, all of whom underwent FDG PET/CT scans.

Disclosures: This study was funded by Health Holland and Pfizer. Four authors declared serving as consultants or advisors for, receiving research grants from, or having other ties with various sources, including Pfizer.

Source: Kleinrensink NJ, Spierings J, Vonkeman HE, et al. Increased vascular inflammation on PET/CT in psoriatic arthritis patients in comparison with controls. RMD open. 2024;10:e003547 (Jan 30). doi: 10.1136/rmdopen-2023-003547 Source